2018
FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors
Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.Peer-Reviewed Original ResearchConceptsSex cord-stromal tumorsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsCell tumorsReticulin patternFOXL2 mutationStaining patternSertoli-Leydig cell tumorFOXL2 mutation statusAbundant pale cytoplasmSingle institutional cohortThird of casesWild-type tumorsFOXL2 mutation analysisNegative tumorsPositive tumorsTumor sizeReticulin stainingType tumorsPale cytoplasmNuclear atypiaMutation statusPositive casesTumors
2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumors